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Pre-mRNA splicing in the absence
of an SR protein RS domain
Jun Zhu and Adrian R. Krainer1
Cold Spring Harbor Laboratory, Cold Spring Harbor, New York 11724, USA, and Molecular and Cellular Biology Program,
State University of New York at Stony Brook, New York 11790, USA
SR proteins are essential pre-mRNA splicing factors that act at the earliest stages of splice-site recognition and
spliceosome assembly, as well as later in the splicing pathway. SR proteins consist of one or two
RNA-recognition motifs and a characteristic arginine/serine-rich C-terminal RS domain. The RS domain,
which is extensively phosphorylated, mediates the subcellular localization of individual SR proteins and also
functions as a splicing activation module, apparently by engaging in protein–protein interactions. The RS
domain of SF2/ASF is dispensable for the concentration-dependent effects of this SR protein on alternative
splice-site selection. However, this RS domain is highly conserved phylogenetically, and was shown to be
required for constitutive splicing in vitro and for cell viability. Here, we demonstrate that the RS domain of
SF2/ASF is, in fact, dispensable for splicing of several substrates, including constitutive and
enhancer-dependent pre-mRNAs. The requirement for this RS domain is substrate specific, and correlates with
the strength of the splicing signals. When the 3 splice site is weak, both the SF2/ASF RS domain and U2AF35
are required for splicing. These results show the existence of an RS domain-independent function of SR
proteins in constitutive and enhancer-dependent splicing, and suggest mechanisms for their role in enhancer
function besides U2AF recruitment.
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Pre-mRNA splicing is a critical step in gene expression
and requires both small nuclear ribonucleoprotein par-
ticles (snRNPs) and non-snRNP protein factors. These
factors assemble into a large complex on the pre-mRNA
known as a spliceosome, which catalyzes splicing (for
review, see Kra¨mer 1996). Members of the SR protein
family are well-studied non-snRNP protein factors re-
quired for pre-mRNA splicing (for review, see Valca´rcel
and Green 1996; Ca´ceres and Krainer 1997). SR proteins
function early in spliceosome assembly to promote the
formation of complexes containing U1 snRNP bound to
the intron 5 splice site and U2 snRNP bound to the
branch site (Krainer et al. 1990b; Wu and Maniatis 1993;
Kohtz et al. 1994; Staknis and Reed 1994; Jamison et al.
1995). SR proteins also function at subsequent stages of
splicing by facilitating the recruitment of U4/U6U5 tri-
snRNP (Roscigno and Garcia-Blanco 1995; Tarn and
Steitz 1995) and by promoting the second transesterifi-
cation step (Chew et al. 1999). In the case of regulated
splicing, SR proteins can modulate alternative splice-site
selection (Ge and Manley 1990; Krainer et al. 1990a), and
also can overcome weak splicing signals by recruiting
components of the general splicing machinery to the in-
tron (for review, see Blencowe 2000).
SR proteins share a distinctive domain structure,
which consists of one or two copies of an RNA-recogni-
tion motif (RRM), followed by a characteristic C-termi-
nal arginine/serine-rich (RS) domain (Birney et al. 1993).
Although the RRMs mediate binding to degenerate se-
quence motifs, they determine the substrate specificity
of individual SR proteins (Chandler et al. 1997; Tacke et
al. 1997; Mayeda et al. 1999; Schaal and Maniatis 1999).
The RS domains are thought to be required for protein–
protein interactions of SR proteins with each other and
with other components of the splicing machinery (Wu
and Maniatis 1993; Kohtz et al. 1994), as well as to me-
diate subcellular localization (Ca´ceres et al. 1997). In
vitro studies showed that the RS domain of the prototype
SR protein SF2/ASF is essential for constitutive splicing,
although the same domain is dispensable for concentra-
tion-dependent effects on alternative splice-site selec-
tion (Ca´ceres and Krainer 1993; Zuo and Manley 1993).
Supporting and extending these initial observations, an
in vivo study in chicken DT40 B-cells showed that the
RS domain of SF2/ASF is essential for cell viability
(Wang et al. 1998b), which is consistent with the high
degree of conservation of this domain (Birney et al. 1993).
Reversible phosphorylation of SR proteins, mainly at
the serine residues within the RS domains, can influence
protein-RNA (Tacke et al. 1997) and protein–protein in-
teractions (Xiao and Manley 1997, 1998), as well as lo-
calization of SR proteins and recruitment to transcrip-
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tionally active sites (for review, see Misteli 1999). The
functional significance of this post-translational modifi-
cation of SR proteins has been demonstrated in systems
in which the activity of these proteins is under tight
control, such as during early development in Ascaris
lumbricoides, sex determination in Drosophila, and dur-
ing adenovirus infection (Du et al. 1998; Kanopka et al.
1998; Sanford and Bruzik 1999).
Several distinct, but not mutually exclusive, functions
have been ascribed to SR proteins. For example, SF2/ASF
can cooperate with the U1 snRNP particle in recognition
of the 5 splice site. This effect is probably mediated by
specific interactions between the RS domains of SF2/
ASF and U1-70K protein (Kohtz et al. 1994; Jamison et al.
1995). SR proteins are also thought to promote splicing
by bridging 5 and 3 splice sites through RS domain-
mediated protein–protein interactions across an intron
or an exon (intron definition or exon definition) (Robber-
son et al. 1990; Wu and Maniatis 1993). Components
that are bound to the 5 and 3 splice sites, such as U1-
70K and U2AF35, also have RS domains and can interact
with the RS domains of SR proteins (Wu and Maniatis
1993; Xiao and Manley 1997). Finally, SR proteins can
recognize exonic splicing enhancers (ESEs) and facilitate
the removal of the adjacent intron(s) (for review, see
Blencowe 2000).
The precise mechanism of ESE function is still un-
clear. Early experiments supported a U2AF65-recruit-
ment model, according to which ESE-bound SR proteins
facilitate U2AF65 binding to the 3 splice site polypy-
rimidine tract via an RS domain-mediated interaction
with U2AF35 (Wu and Maniatis 1993; Wang et al. 1995;
Zuo and Maniatis 1996). In contrast, recent experiments
showed that crosslinking of U2AF65 to the polypyrimi-
dine tract of certain enhancer-dependent pre-mRNAs re-
quires neither the enhancer sequences nor U2AF35 (Guth
et al. 1999; Kan and Green 1999; Li and Blencowe 1999).
Interestingly, depletion of U2AF35 from HeLa nuclear
extract prevents the splicing of certain enhancer-depen-
dent substrates, but not others. Thus, the roles of RS
domain-mediated interactions and of U2AF in enhancer
function and constitutive splicing are more complex
than initially suggested.
We report the unexpected finding that the RS domain
of SF2/ASF is, in fact, dispensable for in vitro splicing of
several, but not all, pre-mRNAs. The requirement for
this domain of SF2/ASF is related to the strength of the
3 splice site and the requirement for U2AF35. These
results extend our knowledge of the properties of SR pro-
teins, and suggest the existence of RS domain-indepen-
dent functions of these proteins in constitutive and en-
hancer-dependent splicing.
Results
SF2/ASF and mutant proteins
The SR protein SF2/ASF is an essential splicing factor in
vitro when other SR proteins with overlapping functions
are not present. The RS domain of SF2/ASF was thought
to be essential for constitutive splicing, because deletion
of all the RS or SR dipeptides within the RS domain, or
deletion of the entire domain, greatly reduces splicing
efficiency in an S100 extract complementation assay
(Ca´ceres and Krainer 1993; Zuo and Manley 1993). For
technical reasons, these and other SF2/ASF mutants ana-
lyzed in previous work were prepared as N-terminal his-
tagged proteins. Such tags may, in some cases, interfere
with a protein’s normal functions, although in the case
of SF2/ASF, the wild-type his-tagged protein has strong
complementing activity. In this study, we made un-
tagged SF2/ASF lacking the RS domain (RS) to re-exam-
ine the RS domain requirement for in vitro splicing. Al-
though RS domains from different SR proteins vary in
length and sequence, they can be swapped without com-
promising splicing activity in vitro or cell viability
(Chandler et al. 1997; Wang et al. 1998b; Mayeda et al.
1999). We therefore also designed a mutant form of SF2/
ASF with only 10 consecutive RS dipeptides—RS10—to
test whether a simplified RS domain can functionally
substitute for the natural 51-amino-acid RS domain of
SF2/ASF (Fig. 1A).
Wild-type and mutant forms of SF2/ASF were ex-
pressed in Escherichia coli and purified to apparent ho-
mogeneity (Fig. 1B). Because of the denaturation and re-
naturation steps used during the protein purification pro-
cess, a functional assay was used to ensure that at least
the regions of the protein preceding the RS domain were
correctly folded. The activities of wild-type or mutant
forms of SF2/ASF were initially assayed with 5D16X
-globin pre-mRNA. 5D16X is a model substrate with a
duplicated 5 splice site, and it has been shown that SF2/
ASF can promote selection of the proximal 5 splice site
Figure 1. SF2/ASF and variant proteins. (A) Diagram of SF2/
ASF, RS, and RS10 proteins, showing relevant domains. The
RNP-2 and RNP-1 submotifs of RRM1, the Gly-rich hinge,
RRM2, and the RS domain are indicated, and the residue num-
bers at the boundaries of each module are shown. Changes in
the RS domain relative to the wild-type protein are displayed.
(B) Purity of recombinant SF2/ASF proteins. 0.5 µg of each pro-
tein was analyzed by SDS-PAGE and Coomassie blue staining.
RS domain-independent splicing
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of this pre-mRNA in an RS domain-independent manner
(Krainer et al. 1990a; Ca´ceres and Krainer 1993). In HeLa
nuclear extract, 5D16X pre-mRNA spliced preferen-
tially via the distal 5 splice site. Use of the proximal 5
splice site increased on addition of either wild-type SF2/
ASF, RS, or RS10 (data not shown). These results indi-
cate that all three SF2/ASF proteins are functional, and
therefore, the lack of activity of any of these proteins in
other assays is unlikely to be due to misfolding or aggre-
gation.
Phosphorylation of SF2/ASF mutant proteins
Proper protein phosphorylation and dephosphorylation
within the RS domain of SR proteins is important for
their activities in splicing (for review, see Misteli 1999).
Sequence-specific RNA binding by SR proteins is also
enhanced by RS domain phosphorylation (Tacke et al.
1997). Protein–protein interactions between SR proteins
and other RS domain-containing proteins, as well as
their activities in constitutive and enhancer-dependent
splicing, are differentially affected by phosphorylation
and dephosphorylation (Cao et al. 1997; Xiao and Manley
1997, 1998; Kanopka et al. 1998; Prasad et al. 1999). We
therefore asked whether SF2/ASF RS10 and RS can be
phosphorylated under splicing conditions.
First, phosphorylation of the wild-type and mutant re-
combinant proteins by endogenous kinases present in
the SR protein-deficient HeLa S100 extract was mea-
sured by Western blotting with an antibody specific for
RRM1 of SF2/ASF (Hanamura et al. 1998). Phosphory-
lated SF2/ASF, which has decreased electrophoretic mo-
bility compared with unphosphorylated SF2/ASF, was
detected by 30 min of incubation under splicing condi-
tions. RS10 was also phosphorylated, whereas no phos-
phorylated forms of RS could be detected (Fig. 2A). It is
possible that a substantial change in electrophoretic mo-
bility requires phosphorylation of multiple residues. We
therefore performed a more sensitive test, consisting of
incubating the various SF2/ASF proteins in S100 extract
under splicing conditions in the presence of [-32P]ATP,
followed by immunoprecipitation with the anti-SF2/ASF
antibody, SDS-PAGE, and autoradiography. Consistent
with the Western blot result, no radiolabel was incorpo-
rated into the RS protein. Interestingly, the RS10 pro-
tein was phosphorylated to a greater extent than wild-
type SF2/ASF (Fig. 2B), which may be attributable to a
variety of kinases present in the crude S100 extract.
Additional phosphorylation–immunoprecipitation ex-
periments were done with two recombinant SR protein-
specific kinases, SRPK2 and Clk/Sty (Colwill et al. 1996;
Kuroyanagi et al. 1998; Wang et al. 1998a). In contrast to
the kinases present in the extract, SRPK2 and Clk/Sty
phosphorylated SF2/ASF to a greater extent than they did
RS10 (Fig. 2C,D). This result confirms previous reports
that both kinases specifically recognize the intact RS
domain of an SR protein (Colwill et al. 1996; Wang et al.
1998a). In the case of RS, a trace amount of phosphory-
lation was detected with Clk/Sty, but not SRPK2. These
data are in agreement with the fact that Clk/Sty has a
Figure 2. In vitro phosphorylation of SF2/ASF proteins. (A) 5
pmole of wild-type SF2/ASF (lanes 1,2), RS (lanes 3,4), or RS10
(lanes 5,6) was incubated under splicing conditions for 0 (lanes
1,3,5) or 30 min (lanes 2,4,6). The reactions were carried out in
S100 extract, fractionated by SDS-PAGE, and wild-type and mu-
tant proteins were detected by Western blotting with a mono-
clonal antibody directed against the N terminus of SF2/ASF.
The zero-time point reactions were immediately stopped with
SDS sample buffer. (B) The reactions were carried out in S100
extract in the presence of [-32P]ATP, followed by immunopre-
cipitation with anti-SF2/ASF monoclonal antibody, SDS-PAGE,
and autoradiography. The reactions were incubated on ice or at
30°C for 15 min, as indicated. (C) As in B, but the proteins were
phosphorylated with recombinant Clk/Sty kinase instead of
S100 extract. (D) As in C, but with recombinant SRPK2. (E) The
efficiency of immunoprecipitation of the different SF2/ASF pro-
teins was measured by IP/Western. The proteins before (−) and
after (+) immunoprecipitation were detected by Western blot-
ting with the same anti-SF2/ASF antibody used for immunopre-
cipitation.
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broader range of substrates than SRPK1 (which is closely
related to SRPK2) and may phosphorylate regions of SF2/
ASF other than the RS domain (Colwill et al. 1996). We
conclude that the synthetic RS domain of RS10 is effi-
ciently phosphorylated in the extract under splicing con-
ditions, whereas RS remains unphosphorylated.
The RS domain is not strictly required for constitutive
splicing in vitro
It has been reported that the RS domain of SR proteins is
essential for both constitutive and enhancer-dependent
splicing, as his-tagged SF2/ASF RS cannot complement
S100 in these assays (Ca´ceres and Krainer 1993; Zuo and
Manley 1993; Mayeda et al. 1999). Surprisingly, when we
added untagged RS to S100 extract, it efficiently
complemented -globin pre-mRNA splicing (Fig. 3A). To
extend this observation to additional substrates, adeno-
virus major late (AdML) and Drosophila fushi tarazu (ftz)
pre-mRNAs were tested in S100 complementation as-
says. Both RS and RS10 proteins promoted splicing of
these substrates (Fig. 3B,C). Finally, spliceosome assem-
bly was assayed on native gels, and no differences were
found among the three SF2/ASF proteins (data not
shown). These data show that SF2/ASF does not require
its RS domain for constitutive splicing of several sub-
strates, at least in vitro. Apparently, the presence of a
his-tag at the N terminus of SF2/ASF used in previous
studies somehow sensitizes the protein, such that the
effect of the C-terminal RS domain deletion is exacer-
bated.
RS domain-dependent and RS domain-independent
exonic splicing enhancers
Two models have been proposed for ESE function. In the
first model, binding of U2AF65 to the 3 splice site poly-
pyrimidine tract is stabilized through interactions be-
tween ESE-bound SR proteins and U2AF35 (Wu and Ma-
niatis 1993; Zuo and Maniatis 1996). In the second
model, ESEs promote splicing by antagonizing the effect
of adjacent exonic splicing silencers (ESSs) (Guth et al.
1999; Kan and Green 1999). SR proteins, especially their
RS domains, play a crucial role in the U2AF-recruitment
model, whereas little is known about the mechanistic
basis of the antagonism model. We therefore tested the
SF2/ASF RS domain requirement with two well-charac-
terized ESE-dependent substrates, IgM M1–M2 pre-
mRNA and HIV tat23 pre-mRNA (Watakabe et al. 1993;
Kan and Green 1999; Mayeda et al. 1999). ESE and ESS
elements have been mapped in the 3 exon of both pre-
mRNAs. Interestingly, we observed that the RS domain
of SF2/ASF is required for splicing of IgM M1–M2 pre-
mRNA but not HIV tat23 pre-mRNA in S100 comple-
mentation assays (Fig. 4A,B, cf. lanes 3,4 and 5,6). We
conclude that ESEs can function by different mecha-
nisms, and can be categorized into RS domain-dependent
and RS domain-independent. Moreover, although the RS
Figure 3. RS functions in constitutive splicing. (A) In vitro splicing of -globin pre-mRNA in HeLa nuclear extract (lane 1), S100
extract alone (lane 2), S100 extract complemented by 2, 4, or 8 pmole of recombinant SF2/ASF (lanes 3–5), RS (lanes 6–8), or RS10
(lanes 9–11). In vitro splicing of AdML pre-mRNA (B) or ftz pre-mRNA (C) in HeLa nuclear extract (lane 1), S100 extract alone (lane
2), S100 extract complemented by 4 or 8 pmole of recombinant SF2/ASF (lanes 3,4), RS (lanes 5,6), or RS10 (lanes 7,8).
RS domain-independent splicing
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domain of SF2/ASF is not required for constitutive splic-
ing of all pre-mRNAs, it can have substrate-specific
functions that make it essential for splicing of certain
pre-mRNAs. Supporting this idea, the RS domain of SF2/
ASF is required for several other substrates tested, as
shown below in Figures 5 and 6.
Ten RS dipeptides can functionally substitute
for the entire RS domain of SF2/ASF
As RS is unable to complement an S100 extract for IgM
M1–M2 pre-mRNA splicing, we further tested whether
adding 10 consecutive RS dipeptides to the C terminus of
RS is sufficient to restore splicing activity. RS10
complemented splicing of IgM M1–M2 pre-mRNA, al-
though not as efficiently as wild-type SF2/ASF (Fig. 4A).
Without exception, RS10 promoted splicing of all sub-
strates tested for which no activity was obtained with
RS (Fig. 5; data not shown). Therefore, 10 consecutive
RS dipeptides can replace the entire natural RS domain
of SF2/ASF in the context of splicing in vitro. These re-
sults indicate that a stretch of alternating arginine and
serine residues, in which at least some of the serines are
phosphorylated (Fig. 2), can serve as a minimal interface
for the relevant protein–protein interactions.
An RS domain is required for exon-independent
splicing
One of the proposed functions of SR proteins is to me-
diate protein–protein interactions across the intron dur-
ing spliceosome assembly. Recent evidence showed that
RNA substrates with only one nucleotide of exon se-
quence can undergo the first transesterification step of
the splicing reaction in vitro; this reaction requires SR
proteins, and natural RS domain alone has weak activity
Figure 4. RS domain-dependent and RS
domain-independent exonic splicing en-
hancers. In vitro splicing of IgM M1–M2
pre-mRNA (A) and HIV tat23 pre-mRNA
(B) in HeLa nuclear extract (lane 1), S100
extract alone (lane 2), or S100 extract
complemented by 4 or 8 pmole of recom-
binant SF2/ASF (lanes 3,4), RS (lanes
5,6 ), and RS10 (lanes 7,8). The band
marked with an asterisk is a cleavage prod-
uct unrelated to splicing (Krainer et al.
1990b).
Figure 5. RS domain requirement for exon-independent splic-
ing. Exon-independent lariat formation was tested in S100 ex-
tract complementation assays. A derivative of AdML pre-
mRNA containing only 3 nucleotides of the 5 exon and no 3
exon was incubated in HeLa nuclear extract (lane 1), S100 ex-
tract alone (lane 2), or S100 extract complemented by 6 or 12
pmole of recombinant SF2/ASF (lanes 3,4), RS (lanes 5,6), or
RS10 (lanes 7,8). The intron lariat migrates above the precursor
on the 12% denaturing polyacrylamide gel. The region corre-
sponding to the lariat is shown above the main panel as a 10-fold
longer exposure.
Zhu and Krainer
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(Hertel and Maniatis 1999). Consistent with the previous
report, wild-type SF2/ASF could activate the first step of
exon-independent splicing in S100 extract (Fig. 5, lanes
3,4). The RS domain of SF2/ASF was required for splicing
of the minimal exon substrate, as RS protein failed to
complement (Fig. 5, lanes 5,6). RS10 protein could also
promote lariat formation, albeit much less efficiently
than wild-type SF2/ASF (Fig. 5, lanes 7,8). We conclude
that the RS domain of SF2/ASF is required to mediate
protein–protein interactions across the intron in the ab-
sence of exon sequences, and conversely, exon sequences
are required for SF2/ASF lacking an RS domain to pro-
mote splicing.
The RS domain of SF2/ASF is required for splicing
of a pre-mRNA with a weak 3 splice site
ESEs are thought to be capable of compensating for the
presence of weak splice sites by promoting U2AF65 re-
cruitment to the polypyrimidine tract (Wu and Maniatis
1993; Zuo and Maniatis 1996). If this model is correct,
and RS domain-mediated protein–protein interaction be-
tween U2AF35 and SR proteins is necessary, weakening
the polypyrimidine tract of an RS domain-independent
substrate should result in the SR protein RS domain be-
coming indispensable. To test this prediction, we ana-
lyzed a series of -globin pre-mRNAs with different
polypyrimidine tract strengths (Reed 1989) in S100
complementation assays with SF2/ASF containing or
lacking the RS domain. Py↑, Py↓, and Py are -glo-
bin derivatives with an improved, a weakened, or with-
out a polypyrimidine tract, respectively. As expected, no
significant difference was observed between SF2/ASF
and RS for splicing of Py↑ (Fig. 6A, lanes 3–6). How-
ever, the RS domain of SF2/ASF was required for splicing
of Py↓ pre-mRNA (Fig. 6A, lanes 9–12), although only
low levels of splicing were observed in S100 extract.
With both substrates, the levels of splicing obtained in
the presence of RS10 were intermediate between those
obtained with SF2/ASF and RS (data not shown). No
splicing of Py pre-mRNA was observed under any con-
ditions, as expected (Fig. 6A, lanes 13–18). Because the
RS domain requirement depends on the strength of the
polypyrimidine tract, these results strongly suggest that
the RS domain of SR proteins is required for stable bind-
ing of U2AF65 to a weak polypyrimidine tract.
To measure U2AF65 binding to the Py substrates, UV
cross-linking and immunoprecipitation experiments
were carried out. Consistent with the observation that
U2AF65 binds preferentially to consecutive pyrimidines,
no U2AF65 cross-linking was detected in the absence of
a polypyrimidine tract (Fig. 6B, lanes 9–12). In contrast, a
65-kD band was detected when cross-linking was per-
formed in nuclear extract with either Py↑ or Py↓ pre-
mRNAs (Fig. 6B, lanes 1,5). Striking differences in
U2AF65 cross-linking between Py↑ or Py↓ were ob-
served in S100 complementation reactions. In the ab-
sence of SR proteins, U2AF65 cross-linked to Py↑ but
not to Py↓ (Fig. 6B, lanes 2,6). Adding either SF2/ASF or
RS to the S100 extract increased U2AF65 cross-linking
Figure 6. The RS domain of SF2/ASF is required for splicing of a substrate with a weak polypyrimidine tract. (A) In vitro splicing of
-globin pre-mRNA with an improved (Py↑ ), a weakened (Py↓ ), or no (Py) polypyrimidine tract in HeLa nuclear extract (lanes
1,7,13), S100 extract alone (lanes 2,8,14), or S100 extract complemented by 4 or 8 pmole of recombinant SF2/ASF (lanes 3,4,9,10,15,16)
or RS (lanes 5,6,11,12,17,18). (B) Py↑ , Py↓ or Py pre-mRNAs were incubated in HeLa nuclear extract (lanes 1,5,9), S100 extract
alone (lanes 2,6,10), or S100 extract complemented by 8 pmole of either SF2/ASF (lanes 3,7,11) or RS (lanes 4,8,12) under splicing
conditions for 20 min. The reactions were then irradiated with UV light and digested with RNases A and T1. After immunoprecipi-
tation with anti-U2AF65 monoclonal antibody, the cross-linked U2AF65 was detected by 12% SDS-PAGE and autoradiography. The
sequence at the 3 end of each intron is shown. The branchpoint A is shown in bold, and the four nucleotide changes in Py↓ relative
to Py↑ are indicated.
RS domain-independent splicing
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to Py↑, although not dramatically (Fig. 6B, lanes 3,4). In
contrast, the RS domain of SF2/ASF was required to pro-
mote U2AF65 binding to a weak polypyrimidine tract, in
that SF2/ASF but not RS enhanced U2AF65 cross-link-
ing to Py↓ pre-mRNA (Fig. 6B, lanes 7,8). Consistent
with the functional splicing data, the cross-linking re-
sults demonstrate that at least one RS domain-depen-
dent function of SR proteins is to recruit U2AF65 to a
weak polypyrimidine tract. Considering that RS can
function in the splicing of several substrates, we specu-
late that the splicing activity attributable to the RNA-
binding domain of SF2/ASF is distinct from the interac-
tions that result in U2AF65 binding. Because this portion
of the protein comprises both RRMs, RNA binding is
likely involved, although the precise mechanism of ac-
tion is unclear.
U2AF35 is required for splicing of a substrate
with a weak polypyrimidine tract
The requirement of U2AF35 for in vitro splicing has been
controversial (Zuo and Maniatis 1996; Kan and Green
1999). Depletion of U2AF35 from HeLa nuclear extract
prevents splicing of some enhancer-dependent sub-
strates, but not others, and inconsistent results with the
same substrate have been reported by different laborato-
ries (Guth et al. 1999; Kan and Green 1999). Recently,
site-specific cross-linking experiments showed that
U2AF35 directly contacts the AG dinucleotide at the 3
splice site during a very early step of spliceosome assem-
bly (Merendino et al. 1999; Wu et al. 1999; Zorio and
Blumenthal 1999). The requirement for U2AF35 in splic-
ing appears to be substrate specific, but at least some
introns with a weak polypyrimidine tract depend on the
U2AF35-3 splice site interaction to promote U2AF65
binding and splicing (Wu et al. 1999). The Py↓ sub-
strate, which is RS domain dependent, has a weak poly-
pyrimidine tract, and we therefore tested whether splic-
ing of Py↓ is U2AF35 dependent by depletion and add-
back experiments. Depleted nuclear extract (NE) was
made by passing the HeLa nuclear extract through a
poly(U)-Sepharose column, which removes most of the
U2AF65 and U2AF35, resulting in loss of splicing
(Zamore and Green 1991; MacMillan et al. 1997). With
the strong polypyrimidine tract substrate (Py↑), either
U2AF65 made in bacteria (rU2AF65) or baculovirus-ex-
pressed U2AF65/U2AF35 heterodimer (U2AF65/35)
complemented NE to restore splicing activity (Fig. 7A,
lanes 3,4). In contrast, only U2AF65/35 heterodimer, but
not rU2AF65 alone, restored splicing in NE with the
weak polypyrimidine tract substrate (Py↓) (Fig. 7A,
lanes 7,8; M. Hastings and A.R. Krainer, unpubl.). These
data show that Py↓ is an AG-dependent substrate and
requires U2AF35 for efficient splicing.
To further address the relationship between a U2AF35
requirement for splicing and U2AF65 binding to the poly-
pyrimidine tract, UV cross-linking and immunoprecipi-
tation experiments were carried out in poly(U)-depleted
nuclear extract, to which U2AF65 or U2AF65/35 were
added back (Fig. 7B). No U2AF65 cross-linking was ob-
served in NE, as expected, because most of the U2AF65
and U2AF35 had been depleted (Fig. 7B, lanes 2,6). Add-
ing back either rU2AF65 or U2AF65/35 to NE restored
U2AF65 cross-linking with the Py↑ substrate (Fig. 7B,
lanes 3,4). In contrast, with the Py↓ substrate, cross-
linking of U2AF65 was seen only when both U2AF65 and
U2AF35 were present (Fig. 7B, lane 8). Although U2AF65
was made in bacteria and U2AF65/35 was made in bacu-
lovirus, the extent of U2AF65 cross-linking was compa-
rable with both preparations in the case of the control
Py↑ substrate (Fig. 7B, lanes 3,4) but not the Py↓ sub-
strate (Fig. 7B, lanes 7,8). Likewise, both U2AF prepara-
tions had comparable splicing activity for the Py↑ sub-
strate (Fig. 7A, lanes 3,4) but not the Py↓ substrate
cross-linking (Fig. 7A, lanes 7,8).
These results confirm and extend the in vitro splicing
data, establishing that although U2AF35 is dispensable in
Figure 7. U2AF35 is necessary for splicing of a pre-mRNA with
a weak 3 splice site. (A) In vitro splicing of Py↑ or Py↓ pre-
mRNAs in HeLa nuclear extract (NE; lanes 1,5), U2AF-depleted
nuclear extract (NE) plus 2.4 M NaCl wash (lanes 2,6), and
NE plus 2.4 M wash complemented with 0.3 µg rU2AF65 (lanes
3,7) or 0.5 µg U2AF65/35 (lanes 4,8). (B) UV cross-linking of
U2AF65 to Py↑ (lanes 1–4) or Py↓ (lanes 5–8) under splicing
conditions in HeLa nuclear extract (lanes 1,5), NE plus 2.4 M
wash (lanes 2,6), and NE plus 2.4 M wash complemented with
rU2AF65 (lanes 3,7) or U2AF65/35 (lanes 4,8). The faint band be-
low U2AF65 is a degradation product of U2AF65 in the recom-
binant protein preparations.
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certain situations, it is crucial to stabilize U2AF65 bind-
ing to a weak polypyrimidine tract. Together with the
observation that U2AF35 and SF2/ASF interact directly
(Xiao and Manley 1998), the requirement for both the RS
domain of SF2/ASF and U2AF35 for efficient U2AF65
binding suggests that these two factors act in a linear
pathway. Although it would be of interest to test the
requirement for U2AF35 in the presence of wild-type or
RS domain-deleted SF2/ASF as the sole SR protein, our
efforts to efficiently deplete U2AF from S100 extract and
reconstitute splicing with recombinant proteins have
not been successful.
Discussion
SR protein RS domain requirements for in vitro
splicing
We report here that SF2/ASF lacking the RS domain
(RS) is active in S100 complementation assays with
multiple splicing substrates, suggesting that the RS do-
main of this SR protein is not strictly required for in
vitro splicing. This finding contradicts previous reports
(Ca´ceres and Krainer 1993; Zuo and Manley 1993) and a
likely explanation for the discrepancy stems from the
previous use of N-terminal oligo-histidine tags. We
speculate that an N-terminal tag has a subtle effect on
the structure of RRM1 or the short segment immediately
preceding it, interfering with an interaction that can also
be mediated by the RS domain. For example, SF2/ASF
may interact with another component through two sepa-
rate contacts that are to some extent redundant. As a
precedent, partially redundant signals that mediate the
nuclear localization of SF2/ASF are also present within
its RNA-binding and RS domains (Ca´ceres et al. 1998).
Moreover, the crystal structure of an untagged UP1 frag-
ment of hnRNP A1 shows that the N-terminal RRM1 is
preceded by a short 310 helix that contacts bound nucleic
acid (Ding et al. 1999), and N-terminal his-tagged hnRNP
A1 is less active in splice-site switching in vitro than
untagged protein (L. Manche and A.R. Krainer, unpubl.).
Although protein tags can be very useful for purification
and detection, their use in structure/function studies
should be approached with caution, even when the wild-
type tagged protein is active.
Although our results indicate that the biochemical re-
quirement for the RS domain of SF2/ASF in splicing is
not as stringent as previously thought, they do not imply
that this domain plays no role in splicing. First, although
it is difficult to compare the specific activities of SF2/
ASF and RS proteins, given the required renaturation
steps, the overall trend showed that SF2/ASF is slightly
more active than RS in constitutive splicing. Second,
RS protein was inactive with certain enhancer-depen-
dent or exon-independent substrates, as well as with a
substrate with a weak 3 splice site. These results argue
that although the RS domain of SF2/ASF is dispensable
under many circumstances, it is involved in the splicing
mechanism, and the extent of its involvement is sub-
strate specific. These data also support the notion that
formation of functional spliceosomes can be achieved by
multiple redundant mechanisms. It will be interesting to
further investigate the similarities and differences be-
tween RS domain-dependent and RS domain-indepen-
dent splicing complexes.
We cannot rule out the possibility that an SR protein
RS domain is always required for splicing. If so, RS
protein may function in splicing by somehow recruiting
another SR protein present in trace amounts in the S100
extract, with the latter protein providing its own RS do-
main. Although interactions between SR proteins appear
to be mediated by the respective RS domains, the rest of
the protein may contribute to weak protein–protein in-
teractions. The presumptive weak interaction of SF2
RS with trace endogenous SR proteins may be suffi-
cient for splicing of some substrates, whereas other sub-
strates clearly require SF2/ASF to have its own RS do-
main. In this sense, the mechanistic difference between
RS domain-dependent and RS domain-independent sub-
strates may be quantitative rather than qualitative.
Possible mechanisms for SR protein function
in general splicing
The RS domain of SR proteins can participate in both
protein–RNA and protein–protein interactions. Phos-
phorylation of serines within the RS domain influences
RNA binding of SR proteins in vitro by preventing non-
specific interactions with RNA (Tacke et al. 1997). Pro-
tein–protein interactions between SR proteins and SR-
related splicing factors, such as U1-70K, U2AF35, or SR
protein-specific kinases, are mediated by the RS domains
and regulated by reversible phosphorylation of these do-
mains (Wu and Maniatis 1993; Cao et al. 1997; Xiao and
Manley 1997, 1998; Koizumi et al. 1999; Prasad et al.
1999; Yeakley et al. 1999). However, the data presented
here show that even without the RS domain, SF2/ASF
RS—which is not detectably phosphorylated—remains
functional in S100 complementation assays with many,
but not all, splicing substrates. Therefore, with these
substrates, cycles of phosphorylation and dephosphory-
lation of the RS domain are less critical for splicing than
originally proposed. It also follows that SR proteins can
promote splicing by at least two distinct mechanisms,
which are not mutually exclusive.
First, SR proteins function in an RS domain-dependent
manner, and the requirement for this domain likely re-
flects the importance of RS domain-mediated protein–
protein interactions in removal of certain introns. One
example is exon-independent lariat formation (Hertel
and Maniatis 1999) assayed by S100 extract complemen-
tation. With virtually no exon sequences present, we
find that the RS domain of SF2/ASF is crucial to bridge
the two splice sites together and to promote the first step
of splicing. Similarly, the RS domain of SF2/ASF is re-
quired for recruiting U2AF65 to a -globin substrate with
a weak polypyrimidine tract (Fig. 6). Presumably, these
interactions reflect an intron definition model (Robber-
son et al. 1990), and involve a network of RS domain-
mediated interactions between SF2/ASF, U1-70K and
RS domain-independent splicing
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U2AF65/35 (Wu and Maniatis 1993; Zuo and Maniatis
1996).
The second mechanism by which SR proteins promote
splicing does not require the RS domain. In addition to
our present results with SF2/ASF RS, several observa-
tions support this notion. The RS domain of SF2/ASF
was recently found not to be required for enhancing U1
snRNP binding to alternative 5 splice sites (Eperon et al.
2000). Furthermore, using MS2–RS domain chimeric
proteins to study the trans-activating properties of the
RS domain, it was found that MS2–RS does not function
in S100 extract complementation to enhance splicing via
an MS2 RNA-binding site unless a recombinant SR pro-
tein is also added (Graveley and Maniatis 1998). The ma-
jor difference between MS2–RS and genuine SR proteins
resides in their RNA-binding domains. One explanation
for the incomplete activity of MS2–RS is that the RNA-
binding domain of SR proteins has specific functions in
splicing besides binding to the pre-mRNA.
Little is known at present about the molecular basis
for the RS domain-independent function of SR proteins.
One possibility is that the RRMs of SF2/ASF, or the short
flanking segments, comprise a surface(s) involved in spe-
cific protein–protein interactions, which may or may not
overlap with the interactions mediated by the RS do-
main. For example, the RS domain of SF2/ASF is not
sufficient for interaction with U1-70K, and a GST–SF2/
ASF RS fusion protein can interact with U1-70K, albeit
more weakly than in the presence of the RS domain, in
an apparently RNA-independent manner (Xiao and Man-
ley 1997). The RRMs of SF2/ASF and SRp20 are capable
of interacting with several proteins, although none of
them are known to be involved in splicing (Ge et al.
1998; Elliott et al. 2000). A related question is why some
SR proteins have only one RRM, whereas others have
two. RRM2, which is somewhat atypical (Birney et al.
1993), may have evolved to mediate protein–protein in-
teractions, as well as coordinate RNA binding with
RRM1 (Chandler et al. 1997).
An alternative mechanism of RS domain-independent
SF2/ASF function is that binding via the RRMs to the
pre-mRNA is sufficient to promote splicing by compet-
ing with negative factors, such as hnRNPs (Eperon et al.
2000; for review, see Reed 2000). In the absence of other
components, SF2/ASF lacking the RS domain can bind to
the same sequences recognized preferentially by phos-
phorylated SF2/ASF (Tacke et al. 1997), and it can dis-
place hnRNP A1 (Eperon et al. 2000). The sequence
specificity of several individual SR proteins has been
studied by binding or functional SELEX (Liu et al. 2000,
and references therein). Recognition sites conform to de-
generate, short consensus motifs unique to each SR pro-
tein. Some of these motifs are more prevalent in exons
than in introns (for a given length of RNA) but they
occur multiple times in most exons. Similarly, hnRNP
A1, which antagonizes SF2/ASF in a concentration-de-
pendent manner for alternative 5 splice-site selection
(Mayeda and Krainer 1992) and functions as a silencing
factor for splicing of several pre-mRNAs (Caputi et al.
1999; Del Gatto-Konczak et al. 1999), can bind RNA pro-
miscuously (Abdul-Manan and Williams 1996). These
binding patterns imply that antagonism between posi-
tive and negative splicing factors may be derived from
competition for overlapping pre-mRNA binding sites.
Likewise, RSF1, a Drosophila splicing repressor, may
compete with SR proteins for common binding sites
(Labourier et al. 1999).
SR proteins and exonic splicing enhancers
The mechanism of ESE function has been controversial
with respect to the role of U2AF binding (for review, see
Blencowe 2000). Early experiments supported a U2AF-
recruitment model, in which SR proteins bound to ESEs
promote splicing by facilitating the binding of U2AF65 to
the polypyrimidine tract through an interaction medi-
ated by the RS domains of an SR protein and of U2AF35
(Wu and Maniatis 1993; Zuo and Maniatis 1996). How-
ever, more recent work argues that binding of U2AF65 to
certain ESE-dependent pre-mRNAs does not require in-
teractions mediated by an ESE or U2AF35. Instead, these
ESEs may function in part by antagonizing juxtaposed
silencers (Guth et al. 1999; Kan and Green 1999). More-
over, experiments with transgenic flies showed that a
Drosophila U2AF small subunit lacking the RS domain
is functional in vivo and can activate enhancer-depen-
dent dsx pre-mRNA splicing, as long as the U2AF large
subunit has its RS domain (Rudner et al. 1998). On the
basis of our data ESEs can be divided into RS domain-
dependent and RS domain-independent. It is possible
that for substrates like Py↑ and tat23 pre-mRNAs,
U2AF65 binding to the polypyrimidine tract is not the
rate-limiting step. Thus, the enhancers that function in-
dependently of the RS domain of SF2/ASF may promote
splicing by counteracting certain silencers through com-
petition with the cognate RNA-binding proteins for
overlapping binding sites, and/or by protein–protein in-
teractions between SR proteins and components of the
general splicing machinery other than U2AF65/35. In con-
trast, when binding of U2AF65 to the polypyrimidine
tract is rate limiting, the requirement for the RS domain
of SF2/ASF correlates with the recruitment of U2AF65.
It was recently reported that U2AF35 recognizes the
conserved 3 splice site AG dinucleotide and might sta-
bilize the binding of U2AF65 on specific substrates that
are dependent on the 3 AG for splicing (Merendino et al.
1999; Wu et al. 1999; Zorio and Blumenthal 1999). Sup-
porting and extending this observation, our data show
that both U2AF35 and the RS domain of SF2/ASF are
required for splicing of a substrate with a weak polypy-
rimidine tract (Py↓), and both factors function to stabi-
lize U2AF65 binding to the weak splice site. Although
the RS domain dependence and the U2AF35 dependence
were assayed in different extracts (nuclear vs. S100) for
technical reasons, these results are consistent with the
idea that the RS domain-mediated protein network be-
tween an SR protein and U2AF35/65 is crucial for certain
ESEs to overcome weak 3 splice site signals (Zuo and
Maniatis 1996; Guth et al. 1999).
The U2AF35 requirement for IgM M1–M2 pre-mRNA
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splicing was reported with conflicting results by differ-
ent groups (Guth et al. 1999; Kan and Green 1999), al-
though the positive result shows that U2AF35 is required
at least under some conditions. Significantly, both stud-
ies showed that depletion of U2AF35 does not affect the
extent of cross-linking of U2AF65 to the polypyrimidine
tract. Because we now show that the RS domain of SF2/
ASF is also required for splicing of this substrate, one
possibility is that U2AF35 functions downstream to sta-
bilize SR protein binding to the ESE, which in turn an-
tagonizes the nearby splicing silencer.
Ten RS dipeptides can functionally substitute
for the entire RS domain of SF2/ASF
The RS domains of SR proteins are well characterized
splicing trans-activating domains. RS domains from in-
dividual SR proteins, when fused to the bacteriophage
MS2 coat protein RNA-binding domain, can activate
splicing of substrates with the MS2-binding site replac-
ing an ESE (Graveley and Maniatis 1998). We report here
that RS10, in which the 51-amino-acid RS domain of
SF2/ASF was replaced by 10 consecutive RS dipeptides,
is active in splicing of all substrates tested, including RS
domain-dependent substrates. Moreover, RS10 can be
phosphorylated either by endogenous kinases present in
the S100 extract, or by the recombinant SR protein-spe-
cific kinases SRPK2 and Clk/Sty.
Given that 10 consecutive RS dipeptides linked to the
SF2/ASF RNA-binding domain are sufficient for trans-
activating splicing in vitro, it is surprising to note that
the common features of the C-terminal RS domains of
different SR proteins are limited to the overall composi-
tion and the presence of numerous consecutive RS or SR
dipeptides, even though the RS domains of individual SR
proteins are as highly conserved between true orthologs
as the rest of the protein (Birney et al. 1993). The very
high degree of phylogenetic conservation of the RS do-
main of individual SR proteins is suggestive of a specific
function in vivo for each family member. A similar situ-
ation was reported for U2AF65. Whereas a synthetic RS
domain consisting of seven consecutive RS dipeptides is
sufficient for human U2AF65 to recruit U2 snRNP in
vitro (Valca´rcel et al. 1996), the identical synthetic RS
domain is insufficient for Drosophila U2AF large sub-
unit activity in vivo in the absence of the small subunit
RS domain (Rudner et al. 1998). As suggested previously,
(Ca´ceres et al. 1997, 1998), the high conservation of RS
domain sequences may reflect primarily the unique
properties of individual SR proteins in subnuclear target-
ing and nucleo-cytoplasmic shuttling.
Materials and methods
Construction of SF2/ASF mutants
RS was constructed by subcloning the NdeI–BamHI fragment
of pET19b-RRMRRM of SF2/ASF (Ca´ceres and Krainer 1993)
into the pET9c expression vector (Novagen). RS10 was con-
structed by partial gene replacement, as described (Ca´ceres and
Krainer 1993). Two partially complementary oligonucleotides
(RS10-1, 5-catgggccccgctctggtagccgctccctgtctcgcagccgttcgcgc-3;
RS10-2, 5-cttgaatccttagctacgggagcggctacgagagcgcgaacggctgcgag
aag-3) were annealed and filled in with Sequenase 2.0 (US Bio-
chemical). After digestion with ApaI and BamHI, the resulting
restriction fragment was gel purified and subcloned into the
corresponding sites in pET9c-SF2(R/S) (Krainer et al. 1991). The
procedure inadvertently introduced a 6-nucleotide insertion
preceding the ApaI site, placing a His-Gly dipeptide between
Pro197 and Arg198. In addition, the serine in the penultimate
RS repeat was changed to a cysteine. Although the experiments
in Figures 1–5 were done with the original RS10 preparation, we
have recently reconstructed a correct version of the protein
without insertions or substitutions. This bonafide RS10 prepa-
ration is at least as active as the original one.
Preparation of recombinant proteins
Expression and initial fractionation of untagged recombinant
wild-type and mutant SF2/ASF were essentially as described
(Krainer et al. 1991). Recombinant SF2/ASF was exclusively re-
covered in the pellet after separation by CsCl density gradient
centrifugation and dialysis. The pellet was dissolved and dena-
tured by sonication in buffer D (20 mM Hepes-NaOH at pH 8.0,
0.2 mM EDTA, 5% glycerol (v/v), 1 mM DTT, 0.5 mM PMSF)
containing 0.1 M KCl and 6 M urea, followed by rocking for 1 hr
at 4°C. The protein was purified by Perseptive HS chromatog-
raphy in a Perseptive Biosystem under denaturing conditions in
urea. The combined peak fractions were dialyzed against buffer
D with 0.1 M KCl and 3 M urea and then against the same buffer
without urea. The final protein concentration was determined
by the dye-binding method (BioRad) with BSA as a standard.
RS protein was further purified by Perseptive HQ chromatog-
raphy under urea-denaturing conditions. The final dialysis was
against buffer D with 0.4 M KCl to maintain solubility.
Untagged recombinant U2AF65 was also expressed in the
pET-9c vector and similarly fractionated by CsCl gradient cen-
trifugation. The protein remained soluble after dialysis against
buffer D with 0.1 M KCl. It was purified on a Perseptive HQ
column eluted with a linear gradient from 0.1 M to 1 M NaCl in
buffer D, and the combined peak fractions were dialyzed against
buffer D with 0.1 M KCl. U2AF65/35 heterodimer, kindly pro-
vided by M. Hastings, was prepared as described (Graveley and
Maniatis 1998) by use of a baculovirus stock generously pro-




32P-labeled pre-mRNA substrates were
made by runoff transcription from either linearized templates or
purified PCR products with an SP6 or T7 promoter (Mayeda and
Krainer 1999a). -globin and derivative plasmid templates, ex-
cept Py, have been described (Reed and Maniatis 1986; Reed
1989; Krainer et al. 1990a). HIV-tat, IgM M1–M2, Drosophila
ftz, and AdML were transcribed from plasmids pSP64-HIV-
1tat23, pµM1–M2, pSPftz, and pADML-PAR as described (Inoue
et al. 1990; Krainer et al. 1990b; Watakabe et al. 1993; Chew et
al. 1999). Py was constructed by overlap-extension PCR. Two
sets of PCRs were performed with Py↑ as template. The first
PCR was carried out with primers Py1 (5-gaatacaagcttgctt
ac-3) and Py4 (5-caccaccagcgtccagtgcccaccag-3). The second
PCR used primer Py2 (5-ccggggatccacg-3) and Py3 (5-ctg
gtggggcactggacgctggtggtg-3). The products from the two reac-
tions were then combined and further amplified with primers
RS domain-independent splicing
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Py1 and Py2. The resulting PCR product was digested with
HindIII and BamHI and subcloned into the parent vector. The
exon-independent substrate with only 3 nucleotide of upstream
exon was made by PCR as described (Hertel and Maniatis 1999)
using the primers T7E3, 5-taatacgactcactataggggtgagtactcc
ctctcaaaagc-3 and AdMLPY, 5-agagagagaggaaaaaaaagggaaag
ggtcagc-3, and was transcribed without a 5 cap.
Phosphorylation and immunoprecipitation
Phosphorylation in extracts under splicing conditions was car-
ried out in 10-µL reactions lacking polyvinyl alcohol and labeled
pre-mRNA, and containing 10 pmole of SF2/ASF or mutant pro-
teins and in some cases 0.5 µL [-32P]ATP (5 µCi, 6000 Ci/
mmole). For Westerns and IP/Westerns, anti-SF2/ASF mAb96
was used as described (Hanamura et al. 1998). Phosphorylation
with recombinant kinases was performed in 50 mM Tris-HCl
(pH 7.5), 5 mM MgCl2, 1 mM cold ATP, 0.5 µL [-
32P]ATP, by
use of a 1:10 enzyme to substrate ratio. The reactions were
incubated at 30°C for 15 min. 12.5 µL of a 1:1 slurry of protein
A-agarose coupled with anti-SF2/ASF mAb96 (Hanamura et al.
1998) was added and the total volume was brought up to 400 µL
with IP100 buffer (50 mM Tris-HCl at pH 7.6, 2 mM MgCl2, 100
mM KCl, 0.5 mM DTT, 0.25 % NP40). After rocking at 4°C for
1 hr, the beads were pelleted in a microcentrifuge at 1000 rpm
for 15 sec, followed by washing four times with IP100. Bound
protein was released with SDS-sample buffer and analyzed by
SDS-PAGE and autoradiography.
In vitro splicing assays
HeLa cell nuclear and S100 extracts were prepared as described
(Mayeda and Krainer 1999b). Standard conditions were used for
the splicing reactions (Mayeda and Krainer 1999a). Briefly, 10
fmole of 32P-labeled 7CH3GpppG-capped SP6 or T7 transcripts
were incubated in 10-µL splicing reactions. Each reaction con-
tained either 30% HeLa nuclear extract, or 40% S100 extract
complemented with 5–10 pmole of SF2/ASF (wild-type or mu-
tant) protein. The final MgCl2 concentration varied between
1.6–4.8 mM, depending on the substrate and previously de-
scribed optima. After incubation at 30°C for 2–4 hr, the RNA
was extracted and analyzed on 5.5% or 12% polyacrylamide
denaturing gels, followed by autoradiography.
UV cross-linking and immunoprecipitation
UV crosslinking and immunoprecipitation were carried out es-
sentially as described (Guth et al. 1999; Kan and Green 1999).
Briefly, 37.5-µL standard splicing reactions lacking polyvinyl
alcohol were incubated at 30°C for 20 min, placed on ice, and
exposed to 254-nm UV light at 0.56 J/cm2 in a Spectronics XL-
1000 instrument. RNases A (10 µg) and T1 (100 units) were
added and the reactions were incubated for 15 min at 37°C. The
reactions were then incubated with 48 µL of MC3 monoclonal
antibody culture supernatant (a generous gift from J. Valca´rcel,
EMBL, Heidelberg, Germany) for 1 hr on ice. Twelve microliters
of anti-mouse IgG agarose beads (1:1 suspension) was added and
the total volume brought up to 160 µL with IP100 buffer. After
rocking at 4°C for 1hr, the samples were spun at 1000 rpm for 30
sec to pellet the beads, and the supernatant was removed. The
beads were washed two times with IP500 (same as IP100 but
with 500 mM KCl) and two times with IP100 buffer. Immuno-
precipitated proteins were released by boiling in SDS-sample
buffer, and analyzed by electrophoresis on a 12% SDS-poly-
acrylamide gel followed by autoradiography.
Depletion of HeLa nuclear extract
U2AF65/35 was depleted from HeLa nuclear extract by poly(U)-
Sepharose chromatography (Zamore and Green 1991; MacMil-
lan et al. 1997). Briefly, HeLa nuclear extract was first adjusted
to 1 M KCl by dialyzing against buffer F (20 mM HEPES-KOH at
pH 7.9, 1 M KCl, 3 mM MgCl2, 0.05 % NP-40, 1 mM DTT) with
20% glycerol. Poly(U)-Sepharose 4B (Pharmacia) was washed
with buffer D and equilibrated with buffer F with 10% glycerol.
Dialyzed nuclear extract was loaded on the column and washed
with 10 column volumes of buffer F with 10% glycerol. The
protein-peak fractions in the flowthrough were pooled to give
U2AF65/35-depleted extract (NE). The column was eluted se-
quentially with buffer F with 10% glycerol and 2.4 M KCl, and
buffer F with 0.1 M KCl and 2 M guanidine hydrochloride, and
the protein-peak fractions, designated 2.4 M and hU2AF, respec-
tively, were pooled. All three fractions were dialyzed against
buffer D with 0.1 M KCl and stored frozen.
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